MRSN vs TXT · rev $40.5M vs P/E 19, rev $7.52B
Mersana Therapeutics Inc (MRSN) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
MRSN currently screens at market cap $145.4M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the MRSN and TXT stock pages for the full models.
Not investment advice.